NCT00955396已完成1 期
A Randomized, Double-blind, Placebo-controlled Cross-over Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Biogen
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Change in 24 h average SBP and DBP from Baseline to Day 36.
研究概览
简要总结
In this study the investigators will determine whether there is any effect of GSK1014802 on ambulatory blood pressure. This will be a randomized, double-blind, placebo-controlled, repeat dose, 2 period cross-over study conducted in healthy male and female subjects. Approximately 60 subjects will be randomised to receive GSK1014802 400 mg bid and placebo for 36 days with at least 1 week between treatment sessions. A follow-up will occur 7-14 days after the last dose.
详细描述
This study, previously posted by GlaxoSmithKline (GSK), was transitioned to Convergence Pharmaceuticals, Ltd., which spun off from GSK. Convergence Pharmaceuticals, Ltd., has now been acquired by Biogen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male or female between 18 and 65 years of age inclusive.
- •Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests, liver function and cardiac monitoring.
- •A female subject is eligible to participate if she is of:
- •Non-childbearing potential Child-bearing potential and agrees to use a contraception method.
- •Male subjects must agree to use a contraception methods
- •Body weight ≥ 50 kg and BMI within the range 19 - 40.0 kg/m2 (inclusive).
- •Arm circumference ≥ 24 and ≤ 42 cm at mid level.
- •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
排除标准
- •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- •Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- •A positive pre-study drug screen.
- •Alcohol levels above the legal limit for driving at screening and the detection of any alcohol within 24 h prior to the start of dosing in Treatment Periods 1 and
- •A positive test for HIV antibody.
- •History of regular excessive alcohol consumption within 6 months of the study
- •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •Use of prescription or non-prescription drugs, including any antihypertensive agent including diuretics, vitamins, herbal and dietary supplements
- •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy
- •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 90 day period.
- •Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
- •Lactating females.
- •Unwillingness or inability to follow the procedures outlined in the protocol.
- •Subject is mentally or legally incapacitated.
- •Subjects who work at night or whose work schedule includes rotating night time (10:00 PM to 6:00 AM) work.
- •Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
- •Average daily caffeine intake equivalent to > 4 cups of coffee or > 6 cups of tea.
- •Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
- •Consumption of aged cheeses and meats, soy sauce and other tyramine rich sources within 1 day prior to the baseline assessments.
- •Current or past history of symptomatic orthostatic hypotension or history of unexplained vasovagal episode(s).
- •History of known or suspected seizures, including infantile febrile, unexplained significant and recent loss of consciousness or history of significant head trauma with loss of consciousness or a family history (first degree relative) of epilepsy or seizures (fits).
- •Any history of suicidal behaviour or suicidal ideation of type 4 or 5 on the C-SSRS within 3 months of the screening visit.
- •History or currently diagnosed sleep apnea.
研究组 & 干预措施
Period 1
Other
干预措施: GSK1014802 (Drug)
Period 1
Other
干预措施: Placebo (Drug)
Period 2
Other
干预措施: GSK1014802 (Drug)
Period 2
Other
干预措施: Placebo (Drug)
结局指标
主要结局
Change in 24 h average SBP and DBP from Baseline to Day 36.
时间窗: 36 days
次要结局
- PK parameters of GSK1014802 following repeated oral doses of GSK1014802 given twice daily to healthy male and female subjects: Cmax, tmax, AUC(0-12).(36 days)
- Change in day-time outpatient (6:00 AM to 10:00 PM) SBP and DBP from Baseline to Days 15 and 36.(36 days)
- PK/PD analyses to examine the correlation between ambulatory blood pressure and plasma levels and/or metrics of the systemic exposure (Cmax, AUC) of GSK1014802.(36 days)
- Change in 24 h average SBP and DBP from Baseline to Day 15. Change in average SBP and DBP within a dosing interval (12 h) from Baseline to Days 14 and 35.(35 days)
- Change in 24 h average SBP and DBP from Baseline to Days 15 and 36 in subjects with baseline SBP 120-139 mmHg and also DBP 80-89 mmHg.(36 days)
- Change in night-time outpatient (10:00 PM to 6:00 AM) SBP and DBP from Baseline to Days 15 and 36.(36 days)
- Change in 24 h average ambulatory heart rate from Baseline to Days 15 and 36.(36 days)
- Proportion of patients whose 24 h systolic and diastolic BP increased by < 5, 5-9, 1014, 15-19, and > 20 mm Hg compared to baseline.(36 days)
- PK parameters of GSK1014802 following a single oral dose of GSK1014802 to healthy female subjects: Cmax, tmax, AUC (0-t) and, if possible, AUC(0-∞), λz and terminal phase half-life to healthy female subjects.(1 day)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Effectiveness of GSK598809, a Selective D3 Antagonist, Added to CBT and NRT for Smoking Cessation and Relapse PreventionNicotine DependenceNCT01188967Massachusetts General Hospital84
已完成
2 期
Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of AgeAsthmaNCT01156792GlaxoSmithKline162
已完成
1 期
A Study To Investigate Effects Of GSK561679 On Brain Activation During Emotional Processing In Healthy VolunteersDepressive Disorder and Anxiety DisordersNCT00513565GlaxoSmithKline22
已完成
1 期
Study to Test Safety, Tolerability and Blood Levels of GSK971086 After 1 Dose & 7 Days of Dosing in Healthy Adult MalesHealthy SubjectsAndrogen DeficiencyNCT00540553GlaxoSmithKline126
已完成
1 期
Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.Respiratory DisordersNCT01476046GlaxoSmithKline56